Bears, beets, rifaximin.
作者信息
Wang Peter L, Flemming Jennifer A
机构信息
Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
出版信息
Can Liver J. 2021 Nov 11;4(4):438-442. doi: 10.3138/canlivj-2021-0026. eCollection 2021 Fall.
Abstract
摘要
相似文献
1
Bears, beets, rifaximin.
Can Liver J. 2021 Nov 11;4(4):438-442. doi: 10.3138/canlivj-2021-0026. eCollection 2021 Fall.
2
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2.
3
Rifaximin for the treatment of hepatic encephalopathy.
Transplant Proc. 2010 Dec;42(10):4543-7. doi: 10.1016/j.transproceed.2010.09.173.
4
Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
J Assoc Physicians India. 2017 Aug;65(8):42-46.
5
Rifaximin treatment in hepatic encephalopathy.
N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.
6
Rifaximin for the treatment of hepatic encephalopathy.
Pharmacotherapy. 2008 Aug;28(8):1019-32. doi: 10.1592/phco.28.8.1019.
7
Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
Eur J Gastroenterol Hepatol. 2008 Nov;20(11):1064-70. doi: 10.1097/MEG.0b013e328302f470.
8
Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis.
Intern Med. 2021 May 15;60(10):1501-1507. doi: 10.2169/internalmedicine.6039-20. Epub 2020 Dec 22.
9
The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Aliment Pharmacol Ther. 2007 Oct 15;26(8):1147-61. doi: 10.1111/j.1365-2036.2007.03464.x.
10
Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
Rev Gastroenterol Disord. 2005;5 Suppl 1:S10-8.
本文引用的文献
1
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2.
2
Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin.
Pak J Med Sci. 2019 Sep-Oct;35(5):1446-1450. doi: 10.12669/pjms.35.5.549.
3
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.
J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.
4
Rifaximin: beyond the traditional antibiotic activity.
J Antibiot (Tokyo). 2014 Sep;67(9):667-70. doi: 10.1038/ja.2014.106. Epub 2014 Aug 6.
5
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.
Hepatology. 2014 Aug;60(2):715-35. doi: 10.1002/hep.27210. Epub 2014 Jul 8.
6
TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.
World J Gastroenterol. 2014 Mar 14;20(10):2704-14. doi: 10.3748/wjg.v20.i10.2704.
7
Rifaximin treatment in hepatic encephalopathy.
N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.
8
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.
Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d.
9
Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
J Hepatol. 2005 May;42(5):674-9. doi: 10.1016/j.jhep.2004.12.028.
10
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
J Hepatol. 2003 Jan;38(1):51-8. doi: 10.1016/s0168-8278(02)00350-1.
Zotero 插件